Amylyx's ALS Drug Relyvrio Fails Phase 3 Trial, Potential Market Withdrawal
TL;DR Summary
Amylyx's FDA-approved ALS drug, Relyvrio, has failed a crucial Phase III trial, prompting the company to consider withdrawing the drug. In a study of 664 ALS patients, the drug did not outperform a placebo and missed all secondary outcomes, including quality-of-life assessments and muscle function. The failure puts access to the drug in jeopardy and is a significant setback for the treatment of the neurodegenerative disease.
- Amylyx's ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug Endpoints News
- In stunning outcome, Amylyx's ALS drug fails large clinical trial STAT
- Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS Yahoo Finance
- A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market The New York Times
- Amylyx Pharmaceuticals Shares Plummet After Relyvrio Trial Misses Endpoints MarketWatch
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
55%
148 → 66 words
Want the full story? Read the original article
Read on Endpoints News